In B cell malignancies, CD19-targeted CAR-T cells incorporating membrane-bound IL-15 achieved CR with incomplete blood count recovery and MRD negativity (CRi MRD-) lasting for five months in patients with r/r B-ALL. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.